Vertex Pharmaceuticals Inc (VRTX)
397.70
-3.06
(-0.76%)
USD |
NASDAQ |
Apr 25, 16:00
397.77
+0.07
(+0.02%)
After-Hours: 20:00
Vertex Pharmaceuticals Accounts Payable (Quarterly): 364.90M for Dec. 31, 2023
Accounts Payable (Quarterly) Chart
Historical Accounts Payable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 364.90M |
September 30, 2023 | 375.90M |
June 30, 2023 | 363.00M |
March 31, 2023 | 323.20M |
December 31, 2022 | 303.90M |
September 30, 2022 | 126.90M |
June 30, 2022 | 198.00M |
March 31, 2022 | 173.60M |
December 31, 2021 | 195.00M |
September 30, 2021 | 127.86M |
June 30, 2021 | 127.53M |
March 31, 2021 | 127.84M |
December 31, 2020 | 155.10M |
September 30, 2020 | 107.79M |
June 30, 2020 | 101.45M |
March 31, 2020 | 100.70M |
December 31, 2019 | 87.61M |
September 30, 2019 | 92.53M |
June 30, 2019 | 77.04M |
March 31, 2019 | 82.26M |
December 31, 2018 | 110.99M |
September 30, 2018 | 92.15M |
June 30, 2018 | 83.03M |
March 31, 2018 | 74.06M |
December 31, 2017 | 73.99M |
Date | Value |
---|---|
September 30, 2017 | 77.14M |
June 30, 2017 | 75.94M |
March 31, 2017 | 63.14M |
December 31, 2016 | 61.45M |
September 30, 2016 | 50.91M |
June 30, 2016 | 51.30M |
March 31, 2016 | 75.22M |
December 31, 2015 | 74.94M |
September 30, 2015 | 78.90M |
June 30, 2015 | 72.70M |
March 31, 2015 | 43.52M |
December 31, 2014 | 71.19M |
September 30, 2014 | 38.47M |
June 30, 2014 | 55.36M |
March 31, 2014 | 49.57M |
December 31, 2013 | 49.33M |
September 30, 2013 | 51.53M |
June 30, 2013 | 48.57M |
March 31, 2013 | 59.63M |
December 31, 2012 | 101.29M |
September 30, 2012 | 83.73M |
June 30, 2012 | 59.35M |
March 31, 2012 | 73.23M |
December 31, 2011 | 74.64M |
September 30, 2011 | 49.25M |
Accounts Payable Definition
Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.
Accounts Payable (Quarterly) Range, Past 5 Years
77.04M
Minimum
Jun 2019
375.90M
Maximum
Sep 2023
185.78M
Average
127.86M
Median
Sep 2021
Accounts Payable (Quarterly) Benchmarks
Amgen Inc | 1.59B |
Eli Lilly and Co | 2.599B |
Regeneron Pharmaceuticals Inc | 606.60M |
Alpine Immune Sciences Inc | 3.593M |
Moderna Inc | 520.00M |